Navigation Links
Par Pharmaceutical Reports Third Quarter 2008 Results
Date:11/6/2008

p>

For the third quarter ended September 27, 2008, total revenues decreased 30.0% compared with the same period a year earlier as a result of increased competition on the Company's generic products and decreased net sales of Megace(R) ES.

Revenues for the generic products division during the three month period decreased 31.2% to $129.4 million compared with the same period in 2007. Lower generic revenues in 2008 were primarily due to pricing pressure, including for metoprolol, fluticasone, propranolol, ranitidine HCl syrup, various amoxicillin products, cabergoline, and many of the Company's other products. The July 2008 launches of meclizine and dronabinol partially offsetting these declines. Revenues from Strativa decreased 20.3% to $19.6 million compared with the same period in 2007 due to decreased net sales of Megace(R) ES. Net sales growth tempered in 2008 principally due to a more challenging reimbursement environment for Megace(R) ES and included a change in reimbursement status.

Par's third quarter gross margin was 34.5% of sales, compared with 31.2% in 2007. This increase is primarily attributed to increased sales of higher margin meclizine and dronabinol and lower sales of low margin product such as metoprolol, partially offset by lower royalties of ondansetron tablets and lower sales of higher margin products such as propranolol. The gross margin percentage for Strativa was 79.3% in the third quarter of 2008 compared with 78.4% in the same period in 2007, due mainly to a mid-year price increase tempered by increased rebates.

Research and development (R&D) expense decreased 58.0% to $13.8 million in the third quarter of 2008 compared with the same period in 2007, driven primarily by a net reduction in one-time milestone payments.

Third quarter selling, general and administrative (SG&A) expenses decreased by 9.6% to $30.7 million compared with the third quarter of 2007, driven by lower bonus and share-based compensation, and l
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
2. Webcast Alert: Isis Pharmaceuticals Cardiovascular Program Review
3. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
4. Alseres Pharmaceuticals, Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
5. Lotus Pharmaceuticals to Present at Rodman & Renshaw Conference
6. Jazz Pharmaceuticals to Present at Investor Conferences
7. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
8. Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
9. NeoStem Signs Definitive Agreement to Acquire Controlling Interest in a Leading Chinese Pharmaceutical Company
10. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
11. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... December 26, 2014 DW-InductionHeating.com (DaWei Induction ... designing, researching and developing, producing and marketing of a ... the business announces their new series of induction ... of the company, induction brazing refers to ... special filler material and heat. The manager says that ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... about the brain affect the course of a criminal trial, ... a sentence? This was the topic of ... for Neuroscience,s "Neuroscience 2011." Titled "The Brain on Trial: Neuroscience ... neuroscience are both challenging and assisting the judicial system. To ...
... SUNDAY, Dec. 11 (HealthDay News) -- A drug called ... cell anemia can also help young children with the disease, ... younger than 4 years old who took the medication had ... with fever and need for transfusions, the study found. ...
... leukemia patients, own infection-fighting cells appears to protect ... with fludarabine-based chemotherapy, according to new research from ... of Pennsylvania. The new process is a step ... from the commonly prescribed drug, which improves progression-free ...
... SAN DIEGO - A new, targeted approach to treating ... Phase I/II clinical trial for patients with relapsed or ... of the American Society of Hematology. "PCI-32765, one ... cell receptor inhibitors, has shown impressive potential in this ...
... FRIDAY, Dec. 9 (HealthDay News) -- Flu vaccination is easy ... your health during the flu season, but too few Americans ... off concerns about the flu, yet every year it strikes ... to the hospital and killing thousands," Dr. Thomas Slama, president ...
... Terrorist attacks with chemical weapons are a real possibility, ... access journal, Journal of Pharmacy Practice , published by ... how to treat those who have been exposed, pharmacists are ... potential chemical weapons attack. Chemical weapons act on their ...
Cached Medicine News:Health News:The brain on trial 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 2Health News:Adult Sickle Cell Drug May Benefit Kids, Too 3Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 2Health News:Penn researchers repair immune system in leukemia patients following chemotherapy 3Health News:B cell receptor inhibitor causes chronic lymphocytic leukemia remission 2Health News:Americans Encouraged to Get Flu Vaccine 2Health News:Pharmacists crucial in plan for terrorist chemical weapons 2
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Company remains committed to speeding innovation ... pipeline boasts 70 potential medicines in clinical development, including 33 in ... ten potential new medicines in Phase III by the end of ... such as neuroscience, diabetes and oncology, as well as new areas ...
... MISSISSAUGA, Ontario, June 30, 2011 Valeant Pharmaceuticals ... VRX) announced today that its subsidiary, Valeant International ... acquire rights to both Elidel (pimecrolimus 1% cream) ... Meda, an international specialty pharmaceutical company (listed on ...
Cached Medicine Technology:Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 2Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 3
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
Grooved roller, on which knife oscillates....
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
5 mm small, sharp, protected blade. Angled at 105 degrees. Flat handle. Designated most popular model or size....
Medicine Products: